Press Releases from SuppreMol GmbH (1 total)
SuppreMol employs Protagen biomarkers in SLE study
Munich and Dortmund, Germany, August 2, 2011. SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, today announced a collaboration to identify therapy-related biomarkers in patients with Systemic Lupus Erythematosus (SLE).
“We will use the unique biomarker portfolio of Protagen for the rapid identification of autoantibody signatures in the…
